286 related articles for article (PubMed ID: 21232037)
1. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
5. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
6. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
Riganti C; Doublier S; Aldieri E; Orecchia S; Betta PG; Gazzano E; Ghigo D; Bosia A
Eur Respir J; 2008 Aug; 32(2):443-51. PubMed ID: 18385176
[TBL] [Abstract][Full Text] [Related]
7. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
9. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
10. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
Thompson KL; Rosenzweig BA; Zhang J; Knapton AD; Honchel R; Lipshultz SE; Retief J; Sistare FD; Herman EH
Cancer Chemother Pharmacol; 2010 Jul; 66(2):303-14. PubMed ID: 19915844
[TBL] [Abstract][Full Text] [Related]
11. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Hasinoff BB
Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
[TBL] [Abstract][Full Text] [Related]
13. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway.
Yang L; Luo C; Chen C; Wang X; Shi W; Liu J
Br J Pharmacol; 2016 Jan; 173(2):357-71. PubMed ID: 26507774
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
[TBL] [Abstract][Full Text] [Related]
16. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
[TBL] [Abstract][Full Text] [Related]
17. Human Amnion Membrane Proteins Prevent Doxorubicin-Induced Oxidative Stress Injury and Apoptosis in Rat H9c2 Cardiomyocytes.
Faridvand Y; Haddadi P; Vahedian V; Nozari S; Nejabati HR; Pezeshkian M; Afrasiabi A; Safaie N; Jodati A; Nouri M
Cardiovasc Toxicol; 2020 Aug; 20(4):370-379. PubMed ID: 32086724
[TBL] [Abstract][Full Text] [Related]
18. MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Wan GX; Cheng L; Qin HL; Zhang YZ; Wang LY; Zhang YG
Cardiovasc Toxicol; 2019 Jun; 19(3):264-275. PubMed ID: 30535663
[TBL] [Abstract][Full Text] [Related]
19. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
